[{"id":"85a83785-b733-4534-88fe-4b08d1977f8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04126070","created_at":"2021-01-18T20:09:27.547Z","updated_at":"2025-02-25T14:28:48.143Z","phase":"Phase 2","brief_title":"Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors","source_id_and_acronym":"NCT04126070","lead_sponsor":"Xiao X. Wei, MD","biomarkers":" PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/11/2020","start_date":" 05/11/2020","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-29"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"1c16003b-285a-46dd-9a81-5650057a4b2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04336943","created_at":"2021-01-18T20:59:44.586Z","updated_at":"2025-02-25T14:59:00.006Z","phase":"Phase 2","brief_title":"Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load","source_id_and_acronym":"NCT04336943","lead_sponsor":"University of Washington","biomarkers":" BRCA2 • HRD • CDK12 • CHEK2 • BRIP1 • RAD51C • CD4 • RAD51D • NBN • ABRAXAS1 • GEN1","pipe":" | ","alterations":" MSI-H/dMMR • HRD","tags":["BRCA2 • HRD • CDK12 • CHEK2 • BRIP1 • RAD51C • CD4 • RAD51D • NBN • ABRAXAS1 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 04/13/2021","start_date":" 04/13/2021","primary_txt":" Primary completion: 06/20/2024","primary_completion_date":" 06/20/2024","study_txt":" Completion: 06/06/2025","study_completion_date":" 06/06/2025","last_update_posted":"2024-07-02"},{"id":"fe26e061-6fab-4a4a-8b61-386d67bd28a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04030559","created_at":"2021-01-18T19:46:56.442Z","updated_at":"2024-07-02T16:35:22.697Z","phase":"Phase 2","brief_title":"Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects","source_id_and_acronym":"NCT04030559","lead_sponsor":"Marc Dall'Era, MD","biomarkers":" BRCA1 • BRCA2 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • CHEK1 • NBN • FANCL • FANCD2 • GEN1","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • CHEK1 • NBN • FANCL • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/25/2020","start_date":" 02/25/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-01-22"},{"id":"a179cee7-5ed4-48d5-8b29-279b434cdab8","acronym":"PROGRESS","url":"https://clinicaltrials.gov/study/NCT05129605","created_at":"2021-11-22T14:53:36.295Z","updated_at":"2024-07-02T16:35:26.710Z","phase":"","brief_title":"Prostate Cancer Genetic Risk Evaluation and Screening Study","source_id_and_acronym":"NCT05129605 - PROGRESS","lead_sponsor":"Massachusetts General Hospital","biomarkers":" TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • GEN1 • HOXB13","pipe":" | ","alterations":" CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • PMS2 mutation • NBN mutation","tags":["TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • GEN1 • HOXB13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • PMS2 mutation • NBN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/12/2020","start_date":" 02/12/2020","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2023-12-08"},{"id":"611a04a5-f648-4511-92b1-2fb4be2eda4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03845907","created_at":"2021-01-18T18:59:11.958Z","updated_at":"2024-07-02T16:36:46.640Z","phase":"","brief_title":"Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications","source_id_and_acronym":"NCT03845907","lead_sponsor":"Seno Medical Instruments Inc.","biomarkers":" GEN1","pipe":"","alterations":" ","tags":["GEN1"],"overall_status":"Suspended","enrollment":" Enrollment 4","initiation":"Initiation: 12/19/2018","start_date":" 12/19/2018","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2020-04-06"}]